ArticleJournal of virology2010
Human immunodeficiency virus type 1 nucleocapsid p1 confers ESCRT pathway dependence.
Article in Journal of virology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 32 citations in OpenAlex.
- Inositol Hexakisphosphate (IP6) Accelerates Immature HIV-1 Gag Protein Assembly toward Kinetically Trapped Morphologies.Journal of the American Chemical Society · 2022Article
- Article
- How HIV-1 Gag Manipulates Its Host Cell Proteins: A Focus on Interactors of the Nucleocapsid Domain.Viruses · 2020Review
- Membrane dynamics associated with viral infection.Reviews in medical virology · 2016Review
- MicroRNA binding to the HIV-1 Gag protein inhibits Gag assembly and virus production.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- The nucleocapsid domain of Gag is dispensable for actin incorporation into HIV-1 and for association of viral budding sites with cortical F-actin.Journal of virology · 2014Article
- Membrane fission reactions of the mammalian ESCRT pathway.Annual review of biochemistry · 2013Review
- Dynamics of ESCRT proteins.Cellular and molecular life sciences : CMLS · 2012Review
- Role of the SP2 domain and its proteolytic cleavage in HIV-1 structural maturation and infectivity.Journal of virology · 2012Article
- Mechanisms of budding of nanoscale particles through lipid bilayers.The journal of physical chemistry. B · 2012Article
- Budding of retroviruses utilizing divergent L domains requires nucleocapsid.Journal of virology · 2012Article
- ESCRT-independent budding of HIV-1 gag virus-like particles from Saccharomyces cerevisiae spheroplasts.PloS one · 2012Article
- How ubiquitin functions with ESCRTs.Traffic (Copenhagen, Denmark) · 2011Review
- The role of cellular factors in promoting HIV budding.Journal of molecular biology · 2011Review
- Viral infection: Moving through complex and dynamic cell-membrane structures.Communicative & integrative biology · 2011Article
- Host factors involved in retroviral budding and release.Nature reviews. Microbiology · 2011Review
- Membrane budding.Cell · 2010Review
- Cryo electron tomography of native HIV-1 budding sites.PLoS pathogens · 2010Article
- Rescue of HIV-1 release by targeting widely divergent NEDD4-type ubiquitin ligases and isolated catalytic HECT domains to Gag.PLoS pathogens · 2010Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
To facilitate the release of infectious progeny virions, human immunodeficiency virus type 1 (HIV-1) exploits the Endosomal Sorting Complex Required for Transport (ESCRT) pathway by engaging Tsg101 and ALIX through late assembly (L) domains in the C-terminal p6 domain of Gag. However, the L domains in p6 are known to be dispensable for efficient particle production by certain HIV-1 Gag constructs that have the nucleocapsid (NC) domain replaced by a foreign dimerization domain to substitute for the assembly function of NC. We now show that one such L domain-independent HIV-1 Gag construct (termed Z(WT)) that has NC-p1-p6 replaced by a leucine zipper domain is resistant to dominant-negative inhibitors of the ESCRT pathway that block HIV-1 particle production. However, Z(WT) became dependent on the presence of an L domain when NC-p1-p6 was restored to its C terminus. Furthermore, when the NC domain was replaced by a leucine zipper, the p1-p6 region, but not p6 alone, conferred sensitivity to inhibition of the ESCRT pathway. In an authentic HIV-1 Gag context, the effect of an inhibitor of the ESCRT pathway on particle production could be alleviated by deleting a portion of the NC domain together with p1. Together, these results indicate that the ESCRT pathway dependence of HIV-1 budding is determined, at least in part, by the NC-p1 region of Gag.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.